Results 1 to 10 of about 1,187 (129)

A study looking at how missed somatropin injections affect growth in children with growth hormone deficiency: a plain language summary of publication [PDF]

Therapeutic Advances in Endocrinology and Metabolism
• Children with growth hormone deficiency (GHD) are often prescribed a growth hormone called somatropin to help them grow. • As prescribed, somatropin needs to be injected once a day under the skin.
JOSÉ Alvir, Priti Jhingran
exaly   +3 more sources

Understanding the burden of weekly somatrogon injections compared with daily somatropin injections in children with growth hormone deficiency: a plain language summary of publication [PDF]

Therapeutic Advances in Endocrinology and Metabolism
• For children with growth hormone deficiency, once-weekly somatrogon injections were less of a burden than once-daily somatropin injections. • The safety of weekly somatrogon was similar to that of daily somatropin .
Sonya Galcheva
exaly   +3 more sources

Efficacy and safety of once-weekly somatrogon following up to 4 years of treatment in Japanese children with growth hormone deficiency: results from an open-label extension of a phase 3 study [PDF]

Endocrine Journal
Somatrogon is a long-acting recombinant human growth hormone approved in several countries, including Japan, for the treatment of children with growth hormone deficiency (GHD).
Reiko Horikawa, Toshiaki Tanaka, Yukihiro Hasegawa, Tohru Yorifuji, David Ng, Ron G. Rosenfeld, Yuko Hoshino, Akifumi Okayama, Nozomi Ebata, Masayoshi Hosoi, Shinichi Nakamuta, Roy Gomez, Aleksandra Pastrak, Orlando Castellanos   +13 more
doaj   +2 more sources

Improvement in body composition of Japanese participants with Prader-Willi syndrome following somatropin treatment: an open-label, multi cohort Phase 3 study [PDF]

Endocrine Journal
Recombinant human growth hormone (GH; somatropin) treatment has beneficial effects on body composition in patients with Prader-Willi syndrome (PWS).
Masanobu Kawai, Nobuyuki Murakami, Reiko Horikawa, Koji Muroya, Yasuko Fujisawa, Yuko Hoshino, Akifumi Okayama, Takahiro Sato, Nozomi Ebata, Tsutomu Ogata   +9 more
doaj   +2 more sources

Comparing the efficacy and safety of weekly somatrogon with daily somatropin in Asian children living with growth hormone deficiency: a plain language summary of publication [PDF]

Therapeutic Advances in Endocrinology and Metabolism
Summary Key takeaways Children living with growth hormone deficiency (GHD) are usually treated with daily injections of a growth hormone called somatropin to help them grow normally. Somatrogon is a growth hormone treatment that only needs to be injected
Roy Gomez, Vaman Khadilkar, Jayashri Shembalkar, Der-Ming Chu, Cheol Woo Ko, Michael P. Wajnrajch, Ronnie Wang   +6 more
doaj   +2 more sources

Somatrogon in pediatric growth hormone deficiency: a comprehensive review of clinical trials and real-world considerations [PDF]

Annals of Pediatric Endocrinology & Metabolism
Growth hormone (GH) is crucial for childhood growth and body composition. In pediatric GH deficiency (pGHD), the pituitary gland fails to produce sufficient GH, which affects linear growth in childhood.
Aristides K. Maniatis, Michael P. Wajnrajch, Marc Thomas, Sung Beom Chung, Jieun Lee   +4 more
doaj   +2 more sources

Comparing the efficacy and safety of weekly somatrogon with daily somatropin to treat children with growth hormone deficiency: a plain language summary of publication [PDF]

Therapeutic Advances in Endocrinology and Metabolism
• The efficacy of weekly somatrogon injections was no different from that of daily somatropin injections to treat children who don’t make enough growth hormone to grow adequately. ○ Efficacy refers to how well a drug works in a clinical trial. ○ Children
Cheri L. Deal, Joel Steelman, Elpis Vlachopapadopoulou, Renata Stawerska, Lawrence A. Silverman, Moshe Phillip, Ho-Seong Kim, CheolWoo Ko, Oleg Malievskiy, Jose F. Cara, Carl L. Roland, Carrie Turich Taylor, Srinivas Rao Valluri, Michael P. Wajnrajch, Aleksandra Pastrak, Bradley S. Miller   +15 more
doaj   +2 more sources

A database study of the safety and effectiveness of daily growth hormone in treating more than 80,000 children with growth disorders worldwide: a plain language summary of publication [PDF]

Therapeutic Advances in Endocrinology and Metabolism
Summary Researchers looked at data from the largest and longest-running database of children with growth disorders who were treated with daily injections of a brand of growth hormone called Genotropin .
Mohamad Maghnie, Michael B. Ranke, Mitchell E. Geffner, Elpis Vlachopapadopoulou, Lourdes Ibáñez, Martin Carlsson, Wayne Cutfield, Raoul Rooman, Roy Gomez, Michael P. Wajnrajch, Agnès Linglart, Renata Stawerska, Peter E. Clayton, Feyza Darendeliler, Anita C. S. Hokken-Koelega, Reiko Horikawa, Toshiaki Tanaka, Helmuth-Günther Dörr, Michel Polak, Adda Grimberg   +19 more
doaj   +2 more sources

PPP1R12A Mutation Presenting With Congenital Jejunal Atresia and Short Stature: A Pediatric Endocrinology Case Report [PDF]

Case Reports in Pediatrics
We report an 11-year-old Hispanic male with a PPP1R12A gene de novo heterozygous likely pathogenic mutation, p. (Gln13Arg) (CAG>CGG), c.38 A > G in Exon 1 (NM_002480.2), detected on whole-exome trio sequencing during his short-stature evaluation.
Rosita Saul, Maya David, Jordin Frasch, Pedro A. Sanchez-Lara, Bahareh M. Schweiger   +4 more
doaj   +2 more sources

From genotype to phenotype: the impact of early management in pycnodysostosis [PDF]

Endocrinology, Diabetes & Metabolism Case Reports
Summary: Pycnodysostosis (PYCD) is an osteosclerotic skeletal dysplasia caused by mutations in the CTSK gene. We describe four cases, highlighting their clinical progression and therapeutic responses.
Paulo Rafael Gonçalves da Silva Von Zuben, Sophia Zuppo de Sousa, Carolina Costa Figueiredo, Nara Michelle de Araújo Evangelista, Vânia Tonetto Fernandes, Patricia Salmona, Guido de Paula Colares Neto   +6 more
doaj   +2 more sources